All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Principia Biopharma Inc.'s $12.5 million in new money should get the company's lead compound into human trials, but the company is entertaining the idea of partners to advance other prospects arising from its platform that develops reversible, tightly binding covalent therapies.